Ahead of its Capital Markets Day later today, Yourgene has issued an FY22 update indicating results will be in line with upgraded expectations. With Covid-related volumes reducing more rapidly than management expected, a restructuring programme has been initiated to consolidate its UK activities and reduce overheads. We take the opportunity to rebase our estimates, essentially removing all future Covid-related sales and look for a more phased ramp of Core business sales across both Genomic Servi ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY22 update – focussing on the core
- Published:
26 Apr 2022 -
Author:
Chris Glasper -
Pages:
3
Ahead of its Capital Markets Day later today, Yourgene has issued an FY22 update indicating results will be in line with upgraded expectations. With Covid-related volumes reducing more rapidly than management expected, a restructuring programme has been initiated to consolidate its UK activities and reduce overheads. We take the opportunity to rebase our estimates, essentially removing all future Covid-related sales and look for a more phased ramp of Core business sales across both Genomic Servi ....